Pharma Update

Ophthalmology strategy Further improving the standard of care and expanding in new indications Update on key clinical data & outlook Improve outcome across all stages of ocular Vabysmo • New data presented at ASRS 2023: • • ASRS 202. SEATTLE demonstrating reduced risk of epiretinal membrane (ERM) formation vs. aflibercept in patients with DME¹ real-world data reinforcing 1L benefits in DME² and nAMD³ positive anatomical outcomes demonstrated in DME4 and nAMD5 Filed in US and EU Q2/3 2023 in RVO Susvimo (port delivery system) • Return to study enrollment Q4 2023 and US commercialization 2024 • Zifibancimig (VEGF-Ang2 DutaFab) with Ph1b FPI expected Q4 2023 (administration via port delivery system) Ocular Function and Structure Status diseases Earlier stage disease Prevention Anatomic damage Satralizumab Later stage disease ASO factor B BCVA loss Vabysmo Susvimo Today's therapies Blindness Launched Phase II/III OpRegen Restoration Time 1. Glenn et al. ASRS 2023; 2. Gale et al. ASRS 2023, Poster #213; 3. Leng et al. ASRS 2023; 4. Nudleman et al. ASRS 2023; 5. London et al. ASRS 2023; BCVA-Best-corrected visual acuity; DME=Diabetic macular edema; nAMD=Neovascular age-related macular degeneration; RVO=Retinal vein occlusion; FPI-First patient in; ASO=Antisense oligonucleotide 121 Roche

View entire presentation